New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 10, 2014
11:42 EDTGSK, RHHBY, GILDReport claims Tamiflu, Relenza do little to prevent the spread of flu
The Cochrane Collaboration, an independent nonprofit organization that aims to help health professionals, patients, and policy makers access evidence-based medicine to guide their decisions, concluded in a newly published report that neuraminidase inhibitors Tamiflu and Relenza are stockpiled and recommended by public health agencies but have not been proven to prevent the spread of flu or reduce dangerous complications. Tamiflu was co-developed by and is marketed by Gilead Sciences (GILD) and Roche (RHHBY), while Relenza is marketed by GlaxoSmithKline (GSK). Roche said "we disagree with the overall conclusions" and warned they could "potentially have serious public health implications," according to a company statement quoted by BBC News. Reference Link
News For GILD;RHHBY;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 16, 2014
16:00 EDTGILDOptions Update; December 16, 2014
iPath S&P 500 VIX Short-Term Futures up 1.55 to 34.60. Option volume leaders: AAPL TSLA TWTR AMZN FB C GILD BAC NFLX AA MGM MCD according to Track Data.
08:47 EDTRHHBYHemispherx Ampligen provides anti-tumor activity
Subscribe for More Information
05:46 EDTRHHBYRoche launches PCR molecular diagnostic system for point of care environment
Subscribe for More Information
December 15, 2014
05:24 EDTRHHBYExelixis announces Genentech files NDA for cobimetinib, vemurafenib combination
Exelixis (EXEL) announced its collaborator Genentech, a member of the Roche Group (RHHBY), has completed the filing of its New Drug Application, or NDA, with the FDA for cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib for previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation. Cobimetinib has received Fast Track designation by the FDA. Roche submitted a Marketing Authorization Application for the combination to the European Medicines Agency in September of this year. The NDA is based on data from the coBRIM trial, a phase 3 pivotal trial conducted by Genentech in 495 patients with BRAF V600 mutation-positive unresectable locally advanced or metastatic melanoma.
December 12, 2014
09:35 EDTGILDActive equity options trading
Subscribe for More Information
05:52 EDTRHHBYRoche announces retirement of Genentech research head
Subscribe for More Information
December 11, 2014
16:01 EDTGILDOptions Update; December 11, 2014
Subscribe for More Information
11:55 EDTGILDGilead shares look cheap, poised for growth, Barron's says
Subscribe for More Information
07:54 EDTGILDGilead shares poised to continue to advance, says RBC Capital
Subscribe for More Information
December 10, 2014
15:59 EDTGILDGilead sued by SEPTA over price of Hep C drug Sovaldi, WSJ reports
Subscribe for More Information
December 9, 2014
12:22 EDTRHHBYPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
10:23 EDTGSKOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:38 EDTGILDActive equity options trading
Subscribe for More Information
09:10 EDTGSKARIAD takeover rumors rekindled, Independent says
Subscribe for More Information
08:38 EDTGILDGilead price target raised to $130 from $110 at Argus
Subscribe for More Information
07:44 EDTRHHBY, GSKAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
05:37 EDTGSKGlaxoSmithKline downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill downgraded GlaxoSmithKline to Underperform citing a lack of pipeline catalysts and its belief the European pharma sector is close to fair value.
December 8, 2014
16:00 EDTGILDOptions Update; December 8, 2014
Subscribe for More Information
13:32 EDTGSKEpizyme announces results for PRMT5 inhibitor
Subscribe for More Information
10:02 EDTGILDGilead presents follow-up data from Zydelig registrational studies
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use